FF 85 Live! From Houston, The KidneyWk Draft
The Filtrate
Joel Topf @kidneyboy.bsky.social
Sophia Ambruso @sophia-kidney.bsky.social
Nayan Arora @captainchloride.bsky.social
Special Guests
Brian Rifkin @brianrifkin.bsky.social
Anna Gaddy @AnnaGaddy
Editing and Show Notes by
Joel Topf
The Kidney Connection written and performed by Tim Yau
Show Notes
Brian Rifkin and Cristina Popa ascend to co-editors in chief of NephJC.
Paresh Jadav receives the first NephJC Champion award. Dr. Jadav hosted the NephJC night and saved NephJC thousands of dollars. It makes a huge difference in our fund raising. Thank you.
Also a big thank-you to Jade Teakell for buying the cowboy hats!
The first pick of the draft, by Sophia is Fish oil for dialysis: Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis (NEJM)
The second pick, by Brian is FINE-ONE (Bayer Press release)
Rajiv Agarwal’s mediation analysis to show how much of finerenone’s beneficial renal effects are captured by the reduction proteinuria: Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis (PubMed)
Anna has the third pick and it goes to Katherine Tuttle and the REM0DEL Trial: REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide (Science Direct)
Nayan goes off-board and picks a poster by a med student (backed by Testani)
Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure (ClinicalTrials.gov)
For the final pick in the draft Joel went with a little Lilly on Lilly violence: Tirzepatide vs. Dulaglutide Is Associated with Reduced Major Kidney Events in Patients with Type 2 Diabetes, CVD, and Very High-Risk Kidney Diseases (JASN)
Bring out your dead…What’s left on the draft board.
Liberate-D A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury: The Liberation From Acute Dialysis (LIBERATE-D) Randomized Clinical Trial (JAMA)
Atacicept for IgAN A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (NEJM)
Lilia Cervantes crushed it with Community Health Worker Support for Hispanic and Latino Individuals Receiving Hemodialysis: The Navigate-Kidney Randomized Clinical Trial (JAMA)
Tubular Secretion
Brian: Late Breaking and High Impact Clinical Trials. Including Sibe! REGENCY Biopsy Data.
Sophia: Flying Home. No, really it’s the Electrolyte Quiz
Joel: The Poster Session, the Quiz Session, and
Nayan: Flying to AHA to talk about dual-heart-kidney-transplant
Anna: Kidney STARS! and Melanie Hoenig’s session on potassium